AI-based medical company Caption Health has obtained a CE mark for its Caption AI technology platform to detect cardiac disease.

The firm said that its Caption AI platform allows medical professionals to quickly, easily, and accurately monitor heart function and ejection fraction wherever patients are.

The platform, which received 510(k) clearance from the US Food and Drug Administration, has been widely available in the US, said the company.

Caption Health stated that CE accreditation validates the company’s outstanding clinical and regulatory track record as it leverages AI and ultrasound to offer improved cardiac care.

The CE mark also represents the first step in making Caption Health’s technology platform accessible outside of the US.

Caption Health chief medical officer Randolph Martin said: “Our technology harnesses the power of ultrasound and allows diagnostic images to be acquired wherever the patient may be.

“Earlier detection of cardiac issues allows us to impact the course of the disease and improve outcomes.

“This is a big step forward in improving access and addressing the significant unmet need stemming from the increasing global burden of cardiovascular diseases like heart failure and valvular heart disease.”

Caption Health is enabling early cardiac treatment to be available wherever patients are by using the Caption AI platform to offer a practical, affordable solution for cardiac ultrasonography.

Before the widespread use of the platform, patients could only be diagnosed following an ultrasound by certified sonographers in a hospital or other specialised environment, usually after the beginning of symptoms.

Currently, the technology can be used widely to identify heart failure symptoms in high-risk patients in clinics and even at home, reducing unnecessary hospital stays and supporting better clinical results, said the company.